Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Staphylococcus aureus Uncharacterized peptidase SAR1786 (SAR1786) CSB-YP753476SKV
CSB-EP753476SKV
CSB-BP753476SKV
CSB-MP753476SKV
CSB-EP753476SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Threonine--tRNA ligase (thrS), partial CSB-YP753477SKV
CSB-EP753477SKV
CSB-BP753477SKV
CSB-MP753477SKV
CSB-EP753477SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus 50S ribosomal protein L27 (rpmA) CSB-YP753478SKV
CSB-EP753478SKV
CSB-BP753478SKV
CSB-MP753478SKV
CSB-EP753478SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus D-tyrosyl-tRNA (Tyr) deacylase (dtd) CSB-YP753479SKV
CSB-EP753479SKV
CSB-BP753479SKV
CSB-MP753479SKV
CSB-EP753479SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Elongation factor 4 (lepA), partial CSB-YP753480SKV
CSB-EP753480SKV
CSB-BP753480SKV
CSB-MP753480SKV
CSB-EP753480SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Chaperone protein DnaK (dnaK), partial CSB-YP753481SKV
CSB-EP753481SKV
CSB-BP753481SKV
CSB-MP753481SKV
CSB-EP753481SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus DNA repair protein recO (recO) CSB-YP753482SKV
CSB-EP753482SKV
CSB-BP753482SKV
CSB-MP753482SKV
CSB-EP753482SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Superoxide dismutase [Mn/Fe] 1 (sodA) CSB-YP753483SKV
CSB-EP753483SKV
CSB-BP753483SKV
CSB-MP753483SKV
CSB-EP753483SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus N utilization substance protein B homolog (nusB) CSB-YP753484SKV
CSB-EP753484SKV
CSB-BP753484SKV
CSB-MP753484SKV
CSB-EP753484SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus UPF0403 protein SAR1592 (SAR1592) CSB-YP753485SKV
CSB-EP753485SKV
CSB-BP753485SKV
CSB-MP753485SKV
CSB-EP753485SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Segregation and condensation protein A (scpA) CSB-YP753486SKV
CSB-EP753486SKV
CSB-BP753486SKV
CSB-MP753486SKV
CSB-EP753486SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus 3-dehydroquinate synthase (aroB) CSB-YP753487SKV
CSB-EP753487SKV
CSB-BP753487SKV
CSB-MP753487SKV
CSB-EP753487SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Asparagine--tRNA ligase (asnS) CSB-YP753488SKV
CSB-EP753488SKV
CSB-BP753488SKV
CSB-MP753488SKV
CSB-EP753488SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Peptide methionine sulfoxide reductase MsrA 2 (msrA2) CSB-YP753489SKV
CSB-EP753489SKV
CSB-BP753489SKV
CSB-MP753489SKV
CSB-EP753489SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Glucose-specific phosphotransferase enzyme IIA component (crr) CSB-YP753490SKV
CSB-EP753490SKV
CSB-BP753490SKV
CSB-MP753490SKV
CSB-EP753490SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex (odhB) CSB-YP753491SKV
CSB-EP753491SKV
CSB-BP753491SKV
CSB-MP753491SKV
CSB-EP753491SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Protein msa (msa), partial CSB-YP753492SKV1
CSB-EP753492SKV1
CSB-BP753492SKV1
CSB-MP753492SKV1
CSB-EP753492SKV1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-acetyltransferase (dapH) CSB-YP753493SKV
CSB-EP753493SKV
CSB-BP753493SKV
CSB-MP753493SKV
CSB-EP753493SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Putative oligopeptide transport ATP-binding protein oppF2 (oppF2) CSB-YP753494SKV
CSB-EP753494SKV
CSB-BP753494SKV
CSB-MP753494SKV
CSB-EP753494SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus N- (5'-phosphoribosyl)anthranilate isomerase (trpF) CSB-YP753495SKV
CSB-EP753495SKV
CSB-BP753495SKV
CSB-MP753495SKV
CSB-EP753495SKV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>